reason report
constant spread thing deflat continu
bottom line report fairli good result morn
encourag increas guid comment
suggest less like deliv result toward
bottom-end guidanc pharmedium remain headwind
sound like compani continu work toward
resolv situat recent close smallest four
pharmedium plant ms comment call indic
manag expect enter consent decre june
estim consent decre outlin step need
taken get memphi facil back though revenu
segment trail estim distribut much better
drove beat also encourag believ
gener brand price trend consist guidanc
posit surpris pressur
gross margin link though believ continu gener
deflat remain headwind pharma suppli chain
encourag sign stabil seem appear
see spread buy sell-sid price
constant follow quarter remain outperform
reduc pt
pharmedium remain headwind work
resolut call manag provid inform
on-going work pharmedium ceo steve colli explain
compani expect enter consent decre june estim
allow commerci distribut continu open
facil determin need done fix memphi
oper incom still expect lost due
pharmedium woe headwind result
consist prior note link manag explain
believ difficult pharmedium volum return prior
level within next year result took larg
asset impair charg pharmedium quarter perspect
purchas pharmedium fall
disappoint continu headwind present pharmedium
like work address issu recent close
cleveland ms pharmedium plant link manag explain
plant smallest least autom plant four
pharmedium facil last quarter manag explain
pharmedium busi cover fix cost
net debt total capit
ep
estimate lt ep growth base
year price history/av daili volume mil
compani inform svb leerink llc research
revenu present billion dollar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price trend consist guidanc gener may
start show stabil work move away
provid detail price trend guidanc encourag
manag character price trend in-lin expect
highlight guid brand price inflat mid-
singl digit gener deflat mid-to-high single-digit
recent figur provid manag slightli
deflat consist analysi price trend
recent publish link comment teva
teva mp also report thursday
teva call manag explain seen stabil
global gener busi quarterli result
confirm stabil importantli
distributor sound like spread sell-sid buy-sid
price remain rel constant comment sound
encourag still estim gener deflat trend
high singl digit rang percent deflat rate may
constant still think signific headwind estim
teva north america gener busi declin y/i
quarter believ sustain gener deflat remain headwind
believ sector remain risk propos aim lower
brand list price prior note link link link link
adj ep guid increas follow decent result
quarter manag rais adj ep guidanc
follow increas guidanc midpoint
rang back prior manag lower
guidanc last quarter rest guidanc re-affirmed
though manag expect share count lower
manag still share repurchas author
remain repurchas worth share year-to-d
encourag result overal encourag
result despit continu headwind beleagu pharmedium
busi beat oper incom adj ep estim
beat larg driven cost control rel model
cog lower model distribut
lower revenu disappoint rel model cost
control led better expect oper margin like
success control distribut cost note adj
 cost reduc pharmedium remedi cost
highest amount record far remedi
report last quarter one-tim
restructur cost also seem high us addit benefit
quarter posit expens item compani
expect benefit strong result brazil reportedli off-set
headwind pharmedium though revenu pharma segment
trail estim manag explain benefit
script growth result growth largest custom
continu specialti distribut growth revenu oper profit
segment also trail estim sound like
work lash progress well overal encourag
remain op reduc pt follow result
updat model quarter revis guid
rais adj ep estim slightli remain
outperform reduc price target given
broader pressur sector
one pharmaceut distributor estim compani
captur pharmaceut distribut market term revenu
primari differenti distributor compani
focu specialti drug firm relationship estim
compani revenu deriv amerisourcebergen specialti group half
total revenu come oncology-rel busi come
drug compani non-specialti drug servic believ compani concentr
oncology-rel drug posit mani larg pend launch market
compani seem intens focu keep cost lean drive oper
margin expans watch measur everi basi point oper margin expans
quarterwhich view posit furthermor manag tend return signific
portion compani free cash flow back sharehold via common stock repurchas
dividend final abc relationship walgreen signific posit view sinc
walgreen own portion sinc walgreen use primari
distributor stand benefit wba growth market includ increment
volum result wba/ transact well increment volum
narrow network deal recent ink includ deal esrx/tricar optum
prime envis headwind exist includ competit sell-sid
environ on-going risk brand gener inflat rate presid trump potenti
polici around brand price unclear though believ ultim work industri
despit risk believ concern current reflect share
price increment revenu off-set mani headwind view given
abc grow market share seemingli decent brand inflat rate purchas power
wbad growth specialti market rate share outperform
share trade ep estim behind
ntm price-to-earnings histor averag rel ep trade
trade view deserv premium
group mainli abc relationship transact believ
new client win posit renew comp eas higher oper cost
allevi trend gener deflat stabil next month
expect share trade ep would put stock
competit intens amerisourcebergen compet two larg drug distributor
competit among intens could lead
either posit neg earn revis furthermor chain independ
consolid usual one distributor retain contract exampl walgreen
acquisit duan read acquisit long unfavor impact
result larg billion dollar piec busi often
chang hand occurr happen past may happen
futur competit could also lead price eros medco health solut part
esrx repres revenu pre-wag top ten custom repres
revenu pre-wag custom lost could materi advers
impact earn share price custom face financi hardship
abil collect receiv could becom challeng insolv
supplier could also result advers impact financi result stock
price economi impact earn result
brand-nam manufactur buy-sid contract fee-for-servic ff arrang
inflat deflat brand-nam drug usual less impact earn
rel contract ff howev sinc price receiv custom often
inflation-bas compon earn could unfavor impact addit economi
weak fewer peopl actual buy prescript drug due concern discretionari
spend lack health insur compani margin could come pressur
govern regul could advers impact compani
pharmaceut drug distribut industri highli regul state feder agenc
includ fda variou state board law pass
may pass futur intent increas safeti may like result
higher cost exampl radio frequenc identif devic may
prove costli track trace chain custodi technolog
also requir hold valid state-level licens meet variou secur oper
standard failur compli feder state local law could advers impact
compani earn
chang reimburs rate could impact earn effect januari
deficit reduct act dra chang feder upper limit
lowest publish price gener averag manufactur price
health reform set less medicaid
improv patient provid act mippa delay adopt
make public least delay implement set
becom public reimburs compani retail custom come
pressur could advers impact firm sell-sid margin addit
reimburs rate chang awp awp roll back could
unfavor impact earn declin asp reimburs
medicar certain specialti drug could also advers impact result
compani revenu growth rate certain drug use oncolog
come pressur expand warn product safeti label nation coverag
decis could advers impact compani revenu growth rate
reform drug reimburs chang canada could also advers impact
compani earn power
chang due health reform could advers impact compani product
servic highli complex pervas throughout entir healthcar system
extens array reimburs mechan player within industri
includ manag care medicar medicaid pbm supplier materi chang
entiti health reform could impact margin
consolid competitor supplier custom purchas group could
advers impact compani earn
litig alway risk compani subject signific number healthcar law
includ fals claim act whistl blower act law relat sale purchas
pharmaceut product exampl offer remuner provid use certain drug
may illeg case
oper risk compani make acquisit risk integr
could caus cost rise oper issu occur addit compani embark
cost save program well streamlin process could result oper
issu data lost compani new implement program face
challeng could advers impact compani earn share price
implement compani enterpris resourc plan erp system could also
advers impact earn oper
incom statement model fiscal year end septemb mm
good sold
distribut sell administr
total revenu
total revenu
impair intang
amort intang
total revenu
total revenu
weight average number share
employe sever litig
